nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Photosensitivity reaction—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Cisplatin—testicular cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Paraesthesia—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Pruritus—Ifosfamide—testicular cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Zuclopenthixol—Dyspnoea—Etoposide—testicular cancer	0.00117	0.00117	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Zuclopenthixol—Somnolence—Etoposide—testicular cancer	0.00117	0.00117	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Methotrexate—testicular cancer	0.00117	0.00117	CcSEcCtD
Zuclopenthixol—Nausea—Bleomycin—testicular cancer	0.00115	0.00115	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Zuclopenthixol—Vomiting—Dactinomycin—testicular cancer	0.00115	0.00115	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Zuclopenthixol—Rash—Dactinomycin—testicular cancer	0.00114	0.00114	CcSEcCtD
Zuclopenthixol—Decreased appetite—Etoposide—testicular cancer	0.00114	0.00114	CcSEcCtD
Zuclopenthixol—Diarrhoea—Ifosfamide—testicular cancer	0.00114	0.00114	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Etoposide—testicular cancer	0.00113	0.00113	CcSEcCtD
Zuclopenthixol—Body temperature increased—Cisplatin—testicular cancer	0.00113	0.00113	CcSEcCtD
Zuclopenthixol—Fatigue—Etoposide—testicular cancer	0.00113	0.00113	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Zuclopenthixol—Pain—Etoposide—testicular cancer	0.00112	0.00112	CcSEcCtD
Zuclopenthixol—Constipation—Etoposide—testicular cancer	0.00112	0.00112	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Zuclopenthixol—Dizziness—Ifosfamide—testicular cancer	0.0011	0.0011	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Urethral disorder—Methotrexate—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Etoposide—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Nausea—Dactinomycin—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Etoposide—testicular cancer	0.00107	0.00107	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Zuclopenthixol—Vomiting—Ifosfamide—testicular cancer	0.00106	0.00106	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Cisplatin—testicular cancer	0.00105	0.00105	CcSEcCtD
Zuclopenthixol—Rash—Ifosfamide—testicular cancer	0.00105	0.00105	CcSEcCtD
Zuclopenthixol—Dermatitis—Ifosfamide—testicular cancer	0.00105	0.00105	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Zuclopenthixol—Abdominal pain—Etoposide—testicular cancer	0.00104	0.00104	CcSEcCtD
Zuclopenthixol—Body temperature increased—Etoposide—testicular cancer	0.00104	0.00104	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Zuclopenthixol—Tinnitus—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Zuclopenthixol—Asthenia—Cisplatin—testicular cancer	0.00103	0.00103	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—testicular cancer	0.001	0.001	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—testicular cancer	0.000999	0.000999	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—testicular cancer	0.000997	0.000997	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—testicular cancer	0.000995	0.000995	CcSEcCtD
Zuclopenthixol—Nausea—Ifosfamide—testicular cancer	0.000986	0.000986	CcSEcCtD
Zuclopenthixol—Diarrhoea—Cisplatin—testicular cancer	0.00098	0.00098	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—testicular cancer	0.000969	0.000969	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—testicular cancer	0.000967	0.000967	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Etoposide—testicular cancer	0.000966	0.000966	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—testicular cancer	0.000965	0.000965	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—testicular cancer	0.000963	0.000963	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—testicular cancer	0.000963	0.000963	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—testicular cancer	0.000961	0.000961	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—testicular cancer	0.000946	0.000946	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—testicular cancer	0.000943	0.000943	CcSEcCtD
Zuclopenthixol—Asthenia—Etoposide—testicular cancer	0.000941	0.000941	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—testicular cancer	0.000941	0.000941	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—testicular cancer	0.000939	0.000939	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—testicular cancer	0.000939	0.000939	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—testicular cancer	0.000935	0.000935	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—testicular cancer	0.000928	0.000928	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—testicular cancer	0.000925	0.000925	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—testicular cancer	0.000923	0.000923	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—testicular cancer	0.00091	0.00091	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—testicular cancer	0.000907	0.000907	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—testicular cancer	0.000907	0.000907	CcSEcCtD
Zuclopenthixol—Rash—Cisplatin—testicular cancer	0.000903	0.000903	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—testicular cancer	0.000902	0.000902	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—testicular cancer	0.000901	0.000901	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—testicular cancer	0.000901	0.000901	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—testicular cancer	0.000897	0.000897	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—testicular cancer	0.000893	0.000893	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—testicular cancer	0.000893	0.000893	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—testicular cancer	0.000889	0.000889	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—testicular cancer	0.000888	0.000888	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—testicular cancer	0.000884	0.000884	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—testicular cancer	0.000875	0.000875	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—testicular cancer	0.000869	0.000869	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—testicular cancer	0.000868	0.000868	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—testicular cancer	0.000867	0.000867	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—testicular cancer	0.000865	0.000865	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—testicular cancer	0.000865	0.000865	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—testicular cancer	0.000862	0.000862	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—testicular cancer	0.000855	0.000855	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—testicular cancer	0.00085	0.00085	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—testicular cancer	0.000849	0.000849	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—testicular cancer	0.000839	0.000839	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—testicular cancer	0.000836	0.000836	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—testicular cancer	0.000834	0.000834	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—testicular cancer	0.000834	0.000834	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—testicular cancer	0.000834	0.000834	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—testicular cancer	0.000834	0.000834	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—testicular cancer	0.000827	0.000827	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—testicular cancer	0.000826	0.000826	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—testicular cancer	0.000822	0.000822	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—testicular cancer	0.000821	0.000821	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—testicular cancer	0.00082	0.00082	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—testicular cancer	0.000818	0.000818	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000814	0.000814	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—testicular cancer	0.000812	0.000812	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—testicular cancer	0.00081	0.00081	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—testicular cancer	0.00081	0.00081	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—testicular cancer	0.000809	0.000809	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—testicular cancer	0.000808	0.000808	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—testicular cancer	0.000806	0.000806	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—testicular cancer	0.000796	0.000796	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—testicular cancer	0.000792	0.000792	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—testicular cancer	0.000786	0.000786	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—testicular cancer	0.000781	0.000781	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—testicular cancer	0.000779	0.000779	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—testicular cancer	0.000778	0.000778	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—testicular cancer	0.000773	0.000773	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—testicular cancer	0.000771	0.000771	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—testicular cancer	0.000769	0.000769	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—testicular cancer	0.000767	0.000767	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—testicular cancer	0.000766	0.000766	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—testicular cancer	0.000764	0.000764	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—testicular cancer	0.000763	0.000763	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000762	0.000762	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—testicular cancer	0.00076	0.00076	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—testicular cancer	0.000758	0.000758	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—testicular cancer	0.000752	0.000752	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—testicular cancer	0.00075	0.00075	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—testicular cancer	0.000749	0.000749	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—testicular cancer	0.000749	0.000749	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—testicular cancer	0.000748	0.000748	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—testicular cancer	0.000746	0.000746	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—testicular cancer	0.000737	0.000737	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—testicular cancer	0.000735	0.000735	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—testicular cancer	0.000734	0.000734	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—testicular cancer	0.000733	0.000733	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—testicular cancer	0.000723	0.000723	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—testicular cancer	0.000722	0.000722	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—testicular cancer	0.000721	0.000721	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—testicular cancer	0.00072	0.00072	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—testicular cancer	0.00072	0.00072	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—testicular cancer	0.000718	0.000718	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000716	0.000716	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—testicular cancer	0.000711	0.000711	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—testicular cancer	0.000711	0.000711	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—testicular cancer	0.00071	0.00071	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—testicular cancer	0.000707	0.000707	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—testicular cancer	0.000706	0.000706	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—testicular cancer	0.000701	0.000701	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—testicular cancer	0.000701	0.000701	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—testicular cancer	0.0007	0.0007	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—testicular cancer	0.000698	0.000698	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—testicular cancer	0.000694	0.000694	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—testicular cancer	0.000692	0.000692	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—testicular cancer	0.000687	0.000687	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—testicular cancer	0.000683	0.000683	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—testicular cancer	0.00068	0.00068	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000678	0.000678	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—testicular cancer	0.000677	0.000677	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—testicular cancer	0.000672	0.000672	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00067	0.00067	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—testicular cancer	0.000669	0.000669	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—testicular cancer	0.000667	0.000667	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—testicular cancer	0.000666	0.000666	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—testicular cancer	0.000665	0.000665	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—testicular cancer	0.000664	0.000664	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—testicular cancer	0.000661	0.000661	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—testicular cancer	0.00066	0.00066	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000658	0.000658	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—testicular cancer	0.000656	0.000656	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—testicular cancer	0.000654	0.000654	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—testicular cancer	0.000649	0.000649	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—testicular cancer	0.000647	0.000647	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—testicular cancer	0.000647	0.000647	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—testicular cancer	0.000642	0.000642	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—testicular cancer	0.000639	0.000639	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—testicular cancer	0.000636	0.000636	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000635	0.000635	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—testicular cancer	0.000634	0.000634	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—testicular cancer	0.000629	0.000629	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—testicular cancer	0.000629	0.000629	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—testicular cancer	0.000621	0.000621	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—testicular cancer	0.000621	0.000621	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00062	0.00062	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—testicular cancer	0.000615	0.000615	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—testicular cancer	0.000611	0.000611	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—testicular cancer	0.000607	0.000607	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—testicular cancer	0.000606	0.000606	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—testicular cancer	0.000605	0.000605	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—testicular cancer	0.000601	0.000601	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—testicular cancer	0.000599	0.000599	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—testicular cancer	0.000591	0.000591	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—testicular cancer	0.000582	0.000582	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—testicular cancer	0.000582	0.000582	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—testicular cancer	0.000581	0.000581	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—testicular cancer	0.000581	0.000581	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—testicular cancer	0.000579	0.000579	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—testicular cancer	0.000564	0.000564	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—testicular cancer	0.000561	0.000561	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000556	0.000556	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—testicular cancer	0.000556	0.000556	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—testicular cancer	0.000542	0.000542	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—testicular cancer	0.000538	0.000538	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—testicular cancer	0.000538	0.000538	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—testicular cancer	0.000538	0.000538	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—testicular cancer	0.000528	0.000528	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—testicular cancer	0.00052	0.00052	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—testicular cancer	0.00052	0.00052	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—testicular cancer	0.000503	0.000503	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—testicular cancer	0.000501	0.000501	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—testicular cancer	0.0005	0.0005	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—testicular cancer	0.000495	0.000495	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—testicular cancer	0.000495	0.000495	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—testicular cancer	0.000492	0.000492	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—testicular cancer	0.000488	0.000488	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—testicular cancer	0.000486	0.000486	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—testicular cancer	0.000481	0.000481	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—testicular cancer	0.000468	0.000468	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—testicular cancer	0.000467	0.000467	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—testicular cancer	0.000465	0.000465	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—testicular cancer	0.000464	0.000464	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—testicular cancer	0.000463	0.000463	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—testicular cancer	0.000461	0.000461	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—testicular cancer	0.000437	0.000437	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—testicular cancer	0.000433	0.000433	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—testicular cancer	0.000429	0.000429	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—testicular cancer	0.000429	0.000429	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—testicular cancer	0.000426	0.000426	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—testicular cancer	0.000404	0.000404	CcSEcCtD
